Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
A Phase I/II Study of PI3Kγδ Inhibitor Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma Who Have Progressed on Anti-PD1 Therapy
Sponsor: Bristol-Myers Squibb
Terminated
Secura Bio, Inc. discontinued support of the trial.
This PHASE1/PHASE2 trial investigates Unresectable Melanoma and is currently terminated or withdrawn. Bristol-Myers Squibb leads this study, which shows 10 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE1/PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Jan 2026 [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2023 — Jun 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 5 earlier versions
-
May 2022 — Jun 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Mar 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- John Kirkwood
- Secura Bio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .